探讨诊断时所处孕期对妊娠期COVID-19疾病进展的影响
前瞻性队列研究纳入2020年3月18日至2021年9月30日在一家城市医院确诊COVID-19并分娩的1326例孕妇,按诊断孕期分层。诊断时无症状或轻症者进展为中度、重度或危重疾病的比例在各孕期无显著差异(P=.80),复合产科结局亦无显著差异(P=.69)。
要点
- 1326例中90%(1195例)为无症状或轻症感染,436例初始无症状者中45例(10%)出现症状。
- 诊断时无症状或轻症者进展为中度及以上疾病:早孕期4/93(4%)、中孕期18/337(5%)、晚孕期49/836(6%),P=.80。
- 复合产科结局按诊断孕期为早孕期24%、中孕期28%、晚孕期28%,P=.69。
核心结论
- 妊娠期COVID-19疾病进展的频率不因诊断时所处孕期而异。
- 中度、重度或危重疾病发生于近10%的妊娠患者。
研究设计与样本
- 前瞻性队列研究,纳入2020年3月18日至2021年9月30日在一家城市医院确诊COVID-19并分娩的1326例孕妇。
- 入院时及住院、急诊和门诊有症状者普遍接受SARS-CoV-2检测;疾病严重程度按美国国立卫生研究院标准分为无症状、轻症、中度、重度或危重。
- 按COVID-19诊断孕期分层:早孕期103例(8%)、中孕期355例(27%)、晚孕期868例(65%)。
主要发现
- 1326例中1195例(90%)为无症状或轻症感染;436例初始无症状者中45例(10%)出现症状。
- 诊断时无症状或轻症者进展为中度、重度或危重疾病:早孕期4/93(4%)、中孕期18/337(5%)、晚孕期49/836(6%),P=.80。
- 复合产科结局无显著差异:早孕期24%、中孕期28%、晚孕期28%,P=.69。
- 阳性检测14天内入院者中,因COVID-19疾病入院:早孕期3/18(17%)、中孕期20/47(43%)、晚孕期34/574(6%)。
- 早孕期患者年龄更大且合并症更多;各孕期86%的患者为西班牙裔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 infection is associated with increased morbidity in pregnancy and adverse maternal and neonatal outcomes. Little is currently known about how the timing of infection during pregnancy affects these outcomes. OBJECTIVE: This study aimed to evaluate the effect of trimester of COVID-19 infection on disease progression and severity in pregnant patients. STUDY DESIGN: This was a prospective cohort study of pregnant patients diagnosed with COVID-19 infection who delivered at a single urban hospital. Universal testing for SARS-CoV-2 was performed at hospital admission and for symptomatic patients in inpatient, emergency department, and outpatient settings. Disease severity was defined as asymptomatic, mild, moderate, severe, or critical on the basis of National Institutes of Health criteria. We evaluated disease progression from asymptomatic to symptomatic infection and from asymptomatic or mild infection to moderate, severe, or critical illness, and stratified by trimester of COVID-19 diagnosis. Primary outcomes included progression of COVID-19 disease severity and a composite obstetrical outcome, which included delivery at <37 weeks, preeclampsia with severe features, abruption, excess blood loss at delivery (>500 mL for vaginal or >1000 mL for cesarean delivery), and stillbirth. RESULTS: From March 18, 2020 to September 30, 2021, 1326 pregnant patients were diagnosed with COVID-19 and delivered at our institution, including 103 (8%) first-, 355 (27%) second-, and 868 (65%) third-trimester patients. First-trimester patients were older and had more medical comorbidities; 86% of patients in all trimesters were Hispanic. Among patients admitted within 14 days of a positive test, 3 of 18 (17%) first-trimester, 20 of 47 (43%) second-trimester, and 34 of 574 (6%) third-trimester patients were admitted for the indication of COVID-19 illness. Across all trimesters, 1195 (90%) of 1326 COVID-19 infections were asymptomatic or mild, and 45 (10%) of 436 initially asymptomatic patients developed symptoms. Of patients with asymptomatic or mild symptoms at diagnosis, 4 (4%) of 93 first-, 18 (5%) of 337 second-, and 49 (6%) of 836 third-trimester patients developed moderate, severe, or critical illness (P=.80). There was no significant difference in composite obstetrical outcome with respect to trimester of COVID-19 diagnosis (24% first-trimester, 28% second-trimester, 28% third-trimester patients; P=.69). CONCLUSION: Moderate, severe, or critical illness develops in almost 10% of pregnant patients. The frequency of COVID-19 disease progression in pregnancy does not differ by trimester of diagnosis.
引用
- Schell RC, Macias DA, Garner WH, et al. Examining the impact of trimester of diagnosis on COVID-19 disease progression in pregnancy. Am J Obstet Gynecol MFM. 2022. PMID: 35995369. doi:10.1016/j.ajogmf.2022.100728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。